Institution
University of California, Irvine
Education•Irvine, California, United States•
About: University of California, Irvine is a education organization based out in Irvine, California, United States. It is known for research contribution in the topics: Population & Galaxy. The organization has 47031 authors who have published 113602 publications receiving 5521832 citations. The organization is also known as: UC Irvine & UCI.
Papers published on a yearly basis
Papers
More filters
••
Baylor College of Medicine1, Beth Israel Deaconess Medical Center2, Emory University3, Ochsner Medical Center4, Icahn School of Medicine at Mount Sinai5, Cedars-Sinai Medical Center6, University of Tennessee Health Science Center7, University of Texas Health Science Center at San Antonio8, American Association of Clinical Endocrinologists9, Tulane University10, University of Alabama at Birmingham11, Wayne State University12, The American College of Financial Services13, University of California, San Diego14, University of Washington15, University of Miami16, Washington University in St. Louis17, University of California, Irvine18
TL;DR: This chapter discusses the development and use of eicosapentaenoic acid as a treatment for diabetic ketoacidosis and its applications in conventional and regenerative medicine.
680 citations
••
Queen Mary University of London1, University of St. Gallen2, University Medical Center Freiburg3, Dartmouth College4, Baylor College of Medicine5, Newcastle University6, National Institutes of Health7, Queen Mary's College8, University of Oxford9, Mario Negri Institute for Pharmacological Research10, University of California, Irvine11, American Cancer Society12
TL;DR: Aspirin has emerged as the most likely NSAID for use in chemoprevention because of its known cardiovascular benefit and available safety and efficacy data, and coadministration of aspirin with a proton-pump inhibitor is an attractive option.
Abstract: Evidence clearly shows a chemopreventive effect for aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) on colorectal cancer and probably other cancer types; however, data on the risk-benefit profile for cancer prevention are insufficient and no definitive recommendations can be made. Aspirin has emerged as the most likely NSAID for use in chemoprevention because of its known cardiovascular benefit and available safety and efficacy data. Other traditional NSAIDs, particularly sulindac, and selective COX-2 inhibitors are now given to patients at high risk of colorectal cancer, although these drugs do not provide cardioprotection. More studies of aspirin and cancer prevention are needed to define the lowest effective dose, the age at which to initiate therapy, the optimum treatment duration, and the subpopulations for which the benefits of chemoprevention outweigh the risks of adverse side-effects. Although it might be possible to answer some of these questions with longer follow-up of existing clinical trials, randomised controlled trials with new study designs will be needed. Future projects should investigate the effects of aspirin treatment on multiple organ systems. Cancers of interest are colorectal, breast, prostate, lung, stomach, and oesophageal. The main side-effect of aspirin is peptic ulcers; therefore coadministration of aspirin with a proton-pump inhibitor is an attractive option and is under investigation in the AspECT trial.
680 citations
••
University of Tokyo1, Boston University2, Brookhaven National Laboratory3, University of California, Irvine4, California State University, Dominguez Hills5, George Mason University6, Gifu University7, University of Hawaii8, KEK9, Kobe University10, Kyoto University11, Los Alamos National Laboratory12, Louisiana State University13, University of Maryland, College Park14, Massachusetts Institute of Technology15, University of Minnesota16, State University of New York System17, Nagoya University18, Niigata University19, Osaka University20, Seoul National University21, Shizuoka University22, Tohoku University23, Tokai University24, Tokyo Institute of Technology25, University of Warsaw26, University of Washington27
TL;DR: In this paper, a number of different fits to solar neutrino mixing and mass square difference were performed using 1496 days of Super-Kamiokande-I's solar NE data.
680 citations
••
TL;DR: The first IGRB measurement with the Large Area Telescope (LAT) on board the Fermi Gamma-ray Space Telescope (Fermi) used 10 months of sky-survey data and considered an energy range between 200 MeV and 100 GeV.
Abstract: The gamma-ray sky can be decomposed into individually detected sources, diffuse emission attributed to the interactions of Galactic cosmic rays with gas and radiation fields, and a residual all-sky emission component commonly called the isotropic diffuse gamma-ray background (IGRB). The IGRB comprises all extragalactic emissions too faint or too diffuse to be resolved in a given survey, as well as any residual Galactic foregrounds that are approximately isotropic. The first IGRB measurement with the Large Area Telescope (LAT) on board the Fermi Gamma-ray Space Telescope (Fermi) used 10 months of sky-survey data and considered an energy range between 200 MeV and 100 GeV. Improvements in event selection and characterization of cosmic-ray backgrounds, better understanding of the diffuse Galactic emission, and a longer data accumulation of 50 months, allow for a refinement and extension of the IGRB measurement with the LAT, now covering the energy range from 100 MeV to 820 GeV. The IGRB spectrum shows a significant high-energy cutoff feature, and can be well described over nearly four decades in energy by a power law with exponential cutoff having a spectral index of 2.32 plus or minus 0.02 and a break energy of (279 plus or minus 52) GeV using our baseline diffuse Galactic emission model. The total intensity attributed to the IGRB is (7.2 plus or minus 0.6) x 10(exp -6) cm(exp -2) s(exp -1) sr(exp -1) above 100 MeV, with an additional +15%/-30% systematic uncertainty due to the Galactic diffuse foregrounds.
680 citations
••
TL;DR: It is shown that, in rats, food deprivation markedly reduces OEA biosynthesis in the small intestine, and results indicate that OEA is a lipid mediator involved in the peripheral regulation of feeding.
Abstract: Oleylethanolamide (OEA) is a natural analogue of the endogenous cannabinoid anandamide. Like anandamide, OEA is produced in cells in a stimulus-dependent manner and is rapidly eliminated by enzymatic hydrolysis, suggesting a function in cellular signalling. However, OEA does not activate cannabinoid receptors and its biological functions are still unknown. Here we show that, in rats, food deprivation markedly reduces OEA biosynthesis in the small intestine. Administration of OEA causes a potent and persistent decrease in food intake and gain in body mass. This anorexic effect is behaviourally selective and is associated with the discrete activation of brain regions (the paraventricular hypothalamic nucleus and the nucleus of the solitary tract) involved in the control of satiety. OEA does not affect food intake when injected into the brain ventricles, and its anorexic actions are prevented when peripheral sensory fibres are removed by treatment with capsaicin. These results indicate that OEA is a lipid mediator involved in the peripheral regulation of feeding.
680 citations
Authors
Showing all 47751 results
Name | H-index | Papers | Citations |
---|---|---|---|
Daniel Levy | 212 | 933 | 194778 |
Rob Knight | 201 | 1061 | 253207 |
Lewis C. Cantley | 196 | 748 | 169037 |
Dennis W. Dickson | 191 | 1243 | 148488 |
Terrie E. Moffitt | 182 | 594 | 150609 |
Joseph Biederman | 179 | 1012 | 117440 |
John R. Yates | 177 | 1036 | 129029 |
John A. Rogers | 177 | 1341 | 127390 |
Avshalom Caspi | 170 | 524 | 113583 |
Yang Gao | 168 | 2047 | 146301 |
Carl W. Cotman | 165 | 809 | 105323 |
John H. Seinfeld | 165 | 921 | 114911 |
Gregg C. Fonarow | 161 | 1676 | 126516 |
Jerome I. Rotter | 156 | 1071 | 116296 |
David Cella | 156 | 1258 | 106402 |